JAMIE BROCKMAN: Open Payments
NPI 1053075820 · SURPRISE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,706 in 77 payments from 15 companies in 2025. Trend: 2023 $374 · 2024 $1,302 · 2025 $1,706
Food & beverage: $1,706
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $356 |
| Lilly USA, LLC | 12 | $187 |
| Amgen Inc. | 15 | $187 |
| Novo Nordisk Inc | 4 | $173 |
| ABBVIE INC. | 9 | $163 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $163 |
| Sumitomo Pharma America, Inc. | 4 | $101 |
| Abbott Laboratories | 4 | $90 |
| Merck Sharp & Dohme LLC | 3 | $61 |
| Boston Scientific Corporation | 2 | $59 |
Products named: AIRSUPRA, CAPLYTA, Ozempic, FARXIGA, GEMTESA, MOUNJARO, REPATHA, OTEZLA.
Industry payments across AZ — which companies pay providers there.
